Daily Times

Belen Garijo has taken over as CEO at German pharmaceuticals giant Merck — the first woman to singlehandedly run a DAX 30-listed company — as Europe’s top economy debates quotas for greater boardroom equality.

Spanish-born Garijo, 60, who started in the new role on May 1, says she’s not content to be a one-off. “It’s more important to me not to be the last woman at the top of a company than to be the only one,” the trained doctor recently told the newspaper Frankfurter Allgemeine Zeitung.

Garijo previously served as the group’s deputy chief executive officer and head of its healthcare unit.

Her immediate focus will be on Merck’s frontline role in the fight against Covid-19, with Garijo announcing that the firm will scale up deliveries in the months ahead of the lipids used in vaccine production for clients such as Pfizer-BioNTech. “We are turning the house upside down to do that,” Garijo told German news agency DPA.

She is replacing Stefan Oschmann, 63, whose term ended after five years at the helm of the Darmstadt-based, family-owned group, which had never had a female chief executive in its 350-year history.

Garijo, a mother of two and a passionate Real Madrid supporter, is making history as the first solo female leader of a firm listed on Frankfurt’s blue-chip DAX 30 index.

German software group SAP made the first cracks in the glass ceiling in 2019 when it appointed Jennifer Morgan as co-CEO alongside a male executive.

However she bowed out last year after just six months, as SAP decided to switch back to a sole chief executive — Christian Klein — to steer it through the pandemic upheaval.

‘Hard work’

Although Germany has been run by a woman chancellor for nearly 16 years and Christine Lagarde heads the Frankfurt-based European Central Bank, female top executives remain a rare sight in Europe’s leading economy.

Germany’s gender pay gap is also one of the largest in Europe, with women earning about 21 percent less than men on average. But things are changing.

The German government introduced legislation in 2015 requiring women to make up 30 percent of supervisory board seats in large companies, and Chancellor Angela Merkel’s cabinet approved plans in January to introduce similar rules for executive boards. Garijo, who previously ran Sanofi’s European operations, joined Merck’s healthcare unit in 2011.

She has been credited with overhauling the department’s research and development and refocusing attention on fewer drugs with better prospects, boosting sales and profits, according to the Handelsblatt financial newspaper.

Garijo for her part puts her success down to “hard work” and to having seized her chances “when they arose”.

She is not, however, a fan of legal quotas to promote women, even in the face of middling results from voluntary measures by industry.

“I am against all forms of discrimination, including positive discrimination,” she said.